Amneal Pharmaceuticals
AMRX
121 hedge funds and large institutions have $314M invested in Amneal Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 32 reducing their positions, and 32 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 129 → 121 (-8)
6.71% less ownership
Funds ownership: 91.22% → 84.51% (-6.7%)
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
58% less capital invested
Capital invested by funds: $756M → $314M (-$441M)
93% less call options, than puts
Call options by funds: $67K | Put options by funds: $966K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$43M |
| 2 |
Morgan Stanley
New York
|
+$6.96M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$6.87M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.34M |
| 5 |
BlackRock
New York
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.04M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.08M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$4.07M |
AMRX Hedge Fund Activity: Q3 2019 in Review
121 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2019, worth a combined $314M — down 58% from $756M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of AMRX and 24 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 44 added.
The largest buyer was TPG Group Holdings (SBS) Advisors, adding an estimated $43M. The largest seller was Fidelity Investments, cutting an estimated $35.1M.
- 121 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2019, down from 129 in Q2 2019.
- Funds reported $314M of Amneal Pharmaceuticals stock for Q3 2019, down 58% quarter-over-quarter.
- 24 funds opened new Amneal Pharmaceuticals positions in Q3 2019 and 32 closed out, a net change of -8 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2019 was TPG Group Holdings (SBS) Advisors, an estimated $43M added.
- The largest Amneal Pharmaceuticals seller in Q3 2019 was Fidelity Investments, an estimated $35.1M sold.
Based on aggregated 13F filings for Q3 2019.